From Marie Curie's discovery of radium, which opened the century-long exploration of nuclear medicine, to today's precise radiopharmaceuticals becoming a core weapon in combating advanced tumors, nuclear medical technology has continuously evolved, lighting up hope for survival for patients with difficult-to-treat cancers. Recently, the Department of Nuclear Medicine at Wuwei Tumor Hospital in Gansu Province is about to complete all necessary approval procedures, becoming the first medical institution in Gansu Province and a leading facility in Northwest China with clinical application qualifications for radium-223 (²²³Ra). This enables routine α-particle targeted radionuclide therapy for bone metastases in castration-resistant prostate cancer, filling a technological gap in the Northwest region and marking a new milestone in the comprehensive precision diagnosis and treatment capabilities of our hospital's nuclear medicine department.

The Wuwei Heavy Ion Center is equipped with China's first heavy ion therapy system with fully independent intellectual property rights. Since the first patient received carbon ion therapy in November 2018, as of March 15, 2026, over 2,800 patients have been treated for more than 100 types of diseases. Among them, 15 cases of gastric cancer were treated, and this summary is hereby presented.

Gansu Province Wuwei Tumor Hospital has been approved for its first provincial chief scientist project, led by Professor Ye Yancheng to tackle radiation-resistant tumors with carbon ion therapy. Leveraging 30 major research platforms and 9 globally advanced technologies, the hospital is developing a "China Solution" to provide new hope for precise treatment of refractory cancers such as pancreatic cancer and glioblastoma.

Cholangiocarcinoma, often dubbed the "silent killer" due to its insidious onset, rapid progression, and limited treatment options, is now being addressed in Wuwei, Gansu, where a cutting-edge technology hailed as a "national treasure"—heavy ion (carbon ion) therapy—is forging a new lifeline for patients with robust clinical data.

Gansu's first sub-center of the National Clinical Research Center for Digestive Diseases has been established at Wuwei Tumor Hospital. Academician Fan Daiming and other experts joined forces to promote the application of new strategies for risk stratification and sequential screening of upper gastrointestinal cancers, inaugurating a new chapter in the integrated prevention, screening, diagnosis, treatment, and rehabilitation of digestive tumors along the Hexi Corridor.

Carbon ion therapy has demonstrated unique advantages and reliable efficacy for tracheal tumors—whether primary squamous cell carcinoma or adenoid cystic carcinoma of the trachea, or secondary tracheal invasion from other malignancies. The following summarizes our center's recent treatment experiences and data for reference by colleagues and patients alike.

Hold hands with Dongli to enjoy a quantum health lifestyle. The 3A-level ecological garden-style Dongli Hotel has officially opened in the Kangyang (Wellness) Town of Wuwei Tumor Hospital, integrating cultural experiences, quantum healing, and traditional Chinese medicine therapy. It offers diverse accommodation options and professional care services, setting a new benchmark for "culture + wellness + tourism."

The Lanzhou Heavy Ion Center has completed a clinical analysis of 61 rectal cancer patients treated with heavy (carbon) ion therapy, achieving a median survival time of 54 months. For patients with stage III/IV or recurrent/refractory disease, this technology offers significantly extended survival due to its high precision, low side effects, and sphincter-sparing advantages, providing a new treatment option for those ineligible for surgery or resistant to radiotherapy and chemotherapy.